Randomized, Double-blind, Parallel-group Comparative Bioequivalence Trial of MabionCD20 (Mabion SA) Compared to MabThera (rituximab, Roche) in Patients with Rheumatoid Arthritis

Trial Profile

Randomized, Double-blind, Parallel-group Comparative Bioequivalence Trial of MabionCD20 (Mabion SA) Compared to MabThera (rituximab, Roche) in Patients with Rheumatoid Arthritis

Recruiting
Phase of Trial: Phase III

Latest Information Update: 17 Nov 2015

At a glance

  • Drugs Rituximab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Pharmacokinetics; Registrational; Therapeutic Use
  • Sponsors Mabion
  • Most Recent Events

    • 06 Nov 2015 Planned primary completion date changed from 1 Mar 2016 to 1 Dec 2016, as reported by ClinicalTrials.gov.
    • 19 Feb 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top